Targeted drug conjugates: Principles and progress

Advanced Drug Delivery Reviews

Volumn 53, Issue 2, 2001, Pages 171-216

  Garnett, Martin C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anthracyclines; Anti cancer drugs; Anti folates; Enediynes; Immunoconjugates; Immunoglobulins; Macrolide antibiotics; Monoclonal antibodies; Vinca alkaloids

Indexed keywords

ANTIBODIES; CHEMOTHERAPY;

IMMUNOCONJUGATES;

CONTROLLED DRUG DELIVERY;

3' DEAMINO 3' MORPHOLINODOXORUBICIN; ACONITIC ACID; ALDEHYDE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CALICHEAMICIN DERIVATIVE; DAUNORUBICIN MONOCLONAL ANTIBODY CONJUGATE; DEXTRAN; DISULFIDE; DOXORUBICIN; DUOCARMYCIN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; FOLIC ACID DERIVATIVE; GELDANAMYCIN; GEMTUZUMAB OZOGAMICIN; HYDRAZONE DERIVATIVE; IDARUBICIN; MACROLIDE; MAYTANSINE; MITOMYCIN C; MONOCLONAL ANTIBODY; RACHELMYCIN; SCHIFF BASE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; VINDESINE; ZINOSTATIN;

ANTIBODY STRUCTURE; BINDING AFFINITY; CANCER; CELL PH; CHEMOTHERAPY; CLINICAL TRIAL; DISULFIDE BOND; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS;

EID: 0035904966     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00227-7     Document Type: Review

References (224)

1. Pharmacokinetics of peptide and protein drugs
2. Exchange of macromolecules across the circulation
3. Ultrastructure of basement membranes
4. Structural and functional differentiation of microvascular endothelium
5. Transport of molecules across tumor vasculature
6. Pathways of macromolecular tracer transport across venules and small veins
7. Identification and characterisation of the blood vessels of solid tumours that are leaky to circulating macromolecules
8. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier
9. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix
10. Pinocytosis in fibroblasts
11. Coated pits, coated vesicles, and receptor-mediated endocytosis
12. Endocytosis and molecular sorting
13. Intracellular pathways and mechanisms of sorting in receptor-mediated endocytosis
14. Digging into caveolae
15. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway
16. Lysosome membrane permeability: Implications for drug delivery
17. Immunologic and pharmacologic concepts of monoclonal antibodies
18. Penetration and binding of antibodies in experimental human solid tumours grown in mice
19. A quantitative analysis of tumour specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumour expression levels
20. Spatial distribution of tumor specific monoclonal antibodies in human melanoma xenografts
21. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumour xenografts in nude mice
22. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors
23. Therapeutic immunoconjugates
24. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores
25. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
26. Characterisation of immunotoxins active against ovarian cancer cell lines
27. Modes of binding and internalization of monoclonal antibodies to human Melanoma cell lines
28. Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates
29. Quantitation of endocytosis of antibody by a radiolabel method
30. The fate of antibodies bound to the surface of tumor cells in vitro
31. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells
32. Structure and properties of pharmacologically active polymers
33. The crucial role of spacer groups in macromolecular pro-drug design
34. Protein thiolation and reversible protein-protein conjugation, N-succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent
35. Immunoconjugate design: A predictive approach for coupling of daunomycin to monoclonal antibodies
36. Addition of sulphydryl groups to E. coli ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimidate)
37. Synthesis and antitumour activity of the immunoconjugate BR96-Dox
38. A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties
39. Labeling of the oligosaccharide moieties of immunoglobulins
40. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations
41. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen
42. Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates
43. (6-Maleimidocaproly)hydrazone of doxorubicin - A new derivative for the preparation of immunoconjugates of doxorubicin
44. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates
45. More useful maleimide compounds for the conjugation of Fab′ to horseradish peroxidase through thiol groups in the hinge
46. Conjugation of methotrexate to poly (L-lysine) as a potential way to overcome drug resistance
47. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy
48. Preparation and properties of a drug-carrier conjugate showing selective antibody-directed cytotoxicity in vitro
49. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: Implication for future preparation of conjugates
50. The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography
51. Studies on the mechanism of action of an antibody-targetted drug-carrier conjugate
52. Studies on the mechanism of action of an MTX-HSA-MoAb conjugate
53. Methotrexate analogs 23. Synthesis, dihydrofolate reductase affinity, cytotoxicity and in vivo antitumour activity of some putative degradation products of methotrexate-poly(l-Lysine) conjugates
54. Fate of plasma membrane during endocytosis III. Evidence for incomplete breakdown of immunoglobulins in lysosomes of cultured fibroblasts
55. The mechanism of hydrolysis of Schiff bases derived from aliphatic amines
56. Dialdehydes
57. Importance of the antigen binding valency and the nature of the cross-linking bond in ricin A-chain conjugates with antibody
58. Disulfide spacer between methotrexate and poly(D-lysine)
59. Cleavage of disulfide bonds in endocytosed macromolecules, a processing no associated with lysosomes or endosomes
60. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo
61. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats
62. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents
63. A method for the preparation of protein-protein conjugates of predetermined composition
64. Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumour tissue
65. pH studies in human malignant tumors
66. cis-Aconityl spacer between daunomycin and macromolecular carrier; a model of pH sensitive linkage releasing drug from a lysosomotropic conjugate
67. New heterobifunctional protein cross-linking reagent that forms an acid labile link
68. New protein cross-linking reagents that are cleaved by mild acid
69. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity
70. Evaluation in vitro of adriamycin immunoconjugates synthesis using an acid-sensitive hydrazone linker
71. New hydrazone derivatives of adriamycin and their immunoconjugates - A correlation between acid stability and cytotoxicity
72. Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro
73. Studies on amino acid and peptide derivatives of daunorubicine
74. Aminoacid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion
75. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo
76. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies
77. Lysosomal degradation of polymers used as drug carriers
78. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro
79. Drug-polymer conjugates: Potential for improved chemotherapy
80. Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer
81. Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers
82. Effet sur la leucémie 1210 de la souris d'une combinaison par diazotation d'améthoptérine et de γ-globulines de hamsters porteurs de cette leucémie par hétérogreffe
83. Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates
84. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
85. Chemoimmunoconjugates for the treatment of cancer
86. Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumour growth in vivo
87. Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model
88. Uptake of methotrexate linked to an enti-EL4-lymphoma antibody by EL-4 cells
89. Biodistribution and tumour localization of a methotrexate-monoclonal-antibody 791T/36 conjugate in nude mice with human tumour xenografts
90. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumour
91. Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates
92. Targeting, internalisation and cytotoxicity of methotrexate-monoclonal-anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells
93. In vivo antitumour effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1 on MH-15 mouse teratocarcinoma
94. Cytotoxicity of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody
95. Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer
96. Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumour activities
97. Phase 1 clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma
98. Anti-tumour activity of aminopterin-monoclonal antibody conjugates; in vitro, and in vivo comparison with methotrexate monoclonal antibody conjugates
99. Reduction in the toxicity of aminopterin-monoclonal antibody conjugates by leucovorin
100. Effect of tumour necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: Parameters for optimization of therapy
101. A vindesine-Anti-CEA conjugate cytotoxic for human cancer cells in vitro
102. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate
103. Antitumour properties of vindesine-monoclonal antibody conjugates
104. Characterization of the human tumour and normal tissue reactivity of the KS1/4 monoclonal antibody
105. Monoclonal antibody drug conjugates for site-directed cancer chemotherapy; preclinical pharmacology and toxicology studies
106. Antitumour activity of the monoclonal antibody-vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxyanhydride in a nude mouse model of human ovarian cancer
107. Epidermal growth factor receptor-reactive monoclonal antibodies: Xenograft antitumour activity alone and as drug immunoconjugates
108. In vivo antitumour activity of the monoclonal antibody-vinca alkaloid immunoconjugate directed against a solid tumour membrane antigen characterized by heterogeneous expression and non-internalization of antibody-antigen complexes
109. In vivo selection of human tumour cells resistant to monoclonal antibody-vinca alkaloid immunoconjugates
110. Tumour resistance to alkylating agents conferred by mechanisms operative only in vivo
111. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas
112. Murine monoclonal antibody-vinca conjugate KA1/4-DAVLB hydrazide: Phase I studies in patients with adenocarcinoma
113. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728 in single and multiple dose clinical studies
114. Properties of antitumour anthracyclines and new developments in their application: Cain memorial award lecture
115. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog
116. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activity
117. The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies
118. Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity
119. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: Comparative in vitro anti-tumour efficacy of different conjugation methods
120. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug
121. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma
122. The anticancer agent adriamycin can be actively cytotoxic without entering cells
123. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumour activity
124. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing
125. Antigen specific activity of carcinoma reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumour xenograft models
126. Effect of linker variation on the stability, potency, and efficacy of carcinoma reactive BR64-doxorubicin immunoconjugates
127. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
128. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate
129. Antitumour activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats
130. Enhanced delivery improves the efficacy of a tumour specific doxorubicin immunoconjugate in a human brain tumor xenograft model
131. Phase I trial of the anti-lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors
132. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
133. A multi-institutional phase II study of BMS 182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma
134. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates
135. Preclinical investigation of the anti-tumour effects of anti-CD19-idarubicin immunoconjugates
136. Antitumour activity of idarubicin-monoclonal antibody conjugate on multi-drug resistant cells
137. Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-α in mice
138. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers
139. Antitumour effect of 2′-deoxyfluorouridine conjugates against a murine thymoma and colon carcinoma xenografts
140. Taxan-antibody conjugates afford potent cytotoxicity, enhanced solubility and tumor target selectivity
141. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage
142. Inhibition of human tumour growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor
143. Effect of a conjugate of daunomycin and antibodies to rat α-fetoprotein on the growth of α-fetoprotein-producing tumor cells
144. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates
145. Doxorubicin: Monoclonal antibody conjugate for therapy of human cervical carcinoma
146. Daunomycin-immunoglobulin conjugates, uptake and activity in vitro
147. Inhibition of Epstein-Barr-virus-transformed human chronic, lymphocytic leukaemic B cells with monoclonal antibody-adriamycin (doxorubicin) conjugates
148. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates
149. Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin-C dextran conjugate
150. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier
151. Site-specific linkage of methotrexate to monoclonal antibody using an intermediate carrier
152. A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model
153. Preparation, characterization and anti-tumor effects of A5B7-CM-dextran-cisplatin conjugates
154. Selective cytotoxicity against tumour cells by cisplatin complexed to antitumour antibodies via carboxymethyl dextran
155. Polymers in drug delivery: Immunotargeting of carrier-supported cis-platinum complexes
156. Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing ovarian cancer cells
157. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody
158. Specific in vitro anti-tumour activity of methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an intermediary
159. An improved synthesis of a methotrexate-albumin, 791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines
160. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines
161. Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines
162. Human tumour xenografts in anticancer drug development: Iodistribution and therapeutic efficacy of a monoclonal antibody-methotrexate conjugate
163. Biodistribution of methotrexate-monoclonal antibody conjugates and complexes: Experimental and clinical studies
164. The loading rate determines tumour targeting properties of methotrexate-albumin conjugates in rats
165. Development of targeted drug therapy using an anti-osteosarcoma antibody
166. Synthesis of 2′-deoxyuridine and 5-fluoro-2′-deoxyuridine derivatives and evaluation in antibody-targeting studies
167. Conjugates of mitomycin C with the immunoglobulin M monomer fragment of a monoclonal anti-MM46 immunoglobulin M antibody with or without serum albumin as intermediary
168. Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumour targeted drug delivery
169. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. I.influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro
170. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalisation, and subcellular fate
171. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
172. Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)-methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo
173. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line
174. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier
175. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens
176. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physicochemical characterisation
177. 2-targeted conjugates and combined therapy with immunomodulators
178. 5-(2-hydroxyethyl)-l-glutamine]
179. Synthesis and antitumor activity of duocarmycin derivatives: A ring pyrrole compounds bearing cinnamoyl groups
180. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumour specific activation
181. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate
182. CC-1065 and the duocarmycins: Unraveling the keys to a new class of naturally derived DNA alkylating agents
183. Antitumour activity and biochemistry of novel analogs of the antibiotic CC-1065
184. Enhancement of the selectivity and antitumour efficacy of a CC-10-65 analogue through immunoconjugate formation
185. Stabilization of neocarzinostatin nonprotein chromophore by interaction with apoprotein and with HeLa cells
186. Roles of chromophore and apo-protein in neocarzinostatin action
187. Neocarzinostatin in cancer chemotherapy
188. SMANCS and polymer conjugated macromolecular drugs: Advantages in cancer chemotherapy
189. Selective toxicity of neocarzinostatin-monoclonal antibody conjugates to the antigen-bearing human melanoma cell line in vitro
190. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma
191. Follow-up study of patients treated with monoclonal antibody-drug conjugate: Report of 77 cases with colorectal cancer
192. Increased serum stability and prolonged biological survival of neocarzinostatin covalently bound to monoclonal antibodies
193. Neocarzinostatin immunoconjugates: In vitro evaluation of therapeutic potential
194. Kinetics of internalisation and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line K562
195. Mechanism of free and conjugated neocarzinostatin activity: Studies on chromophore and protein uptake using a transferrin-neocarzinostatin conjugate
196. Local administration of monoclonal antibody-drug conjugate: A new strategy to reduce the local recurrence of colorectal cancer
197. Antitumour activity of an immunoconjugate composed of anti-human astrocytoma monoclonal antibody and neocarzinostatin
198. Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts
199. Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragment after administration of avidin
200. Penetration and binding of radiolabeled anti-carcinoembryonic antigen antibodies and their antigen binding fragments in human colon multicellular tumour spheroids
201. Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy
202. 1: A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity
203. Preparation and characterisation of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumour antibiotics
204. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD-33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
205. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
206. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer
207. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676
208. Comparison of the efficacy and safety of gemtuzumab ozogamycin (CMA-676) in patients <60 and >60 years of age with AML in first relapse
209. 1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma
210. 1
211. Antimitotic activity of the potent tumour inhibitor maytansine
212. Immunoconjugates of Geldanamycin and Anti-HER2 monoclonal antibodies: Antiproliferative activity on Human breast carcinoma cell lines
213. erbB2 oncogene inhibition by geldanamycin derivatives: Synthesis, mechanism of action and structure activity relationships
214. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids
215. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
216. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
217. Technology evaluation: C242-DM1, Immunogen Inc.
218. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs